Drug intelligence / Profile preview

CpG oligodeoxynucleotide B344

Development stage
Preclinical
Lead developer
University of Guelph
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

CpG oligodeoxynucleotide B344 (CpG B344) is a synthetic, single-stranded DNA molecule containing unmethylated cytosine-guanine (CpG) motifs, specifically categorized as a Class B CpG ODN. It functions as a potent agonist of Toll-like receptor 9 (TLR9), an endosomal receptor that recognizes pathogen-associated molecular patterns (PAMPs) in the form of DNA. Upon activation, CpG B344 triggers a signaling cascade involving the adapter protein MyD88 and the NF-κB pathway, leading to the maturation of antigen-presenting cells and the secretion of pro-inflammatory cytokines such as IL-12 and IFN-γ. While CpG ODNs are broadly studied across species, the B344 sequence (typically an 18-mer consisting of TCG repeats) is particularly prominent in veterinary research. It is utilized as an immunomodulator and vaccine adjuvant to enhance protective immunity against avian pathogens, including avian influenza virus, *Salmonella enteritidis*, and infectious bursal disease virus.

Other names
CpG ODN B344
02

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on CpG oligodeoxynucleotide B344.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CpG oligodeoxynucleotide B344.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call